Cancer‐associated fibroblasts in nonsmall cell lung cancer: From molecular mechanisms to clinical implications

• Published in: International journal of cancer Vol. 151; no. 8; pp. 1195 - 1215
• Main Authors: Wong, Kit Yee, Cheung, Alvin Ho‐Kwan, Chen, Bonan, Chan, Wai Nok, Yu, Jun, Lo, Kwok Wai, Kang, Wei, To, Ka Fai
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 15-10-2022; Wiley Subscription Services, Inc
• Subjects: Cancer; cancer‐associated fibroblast; Carcinogenesis; Cell proliferation; Chemokines; Chemoresistance; Cytokines; Extracellular matrix; Fibroblasts; Growth factors; heterogeneity; Lung cancer; Lung carcinoma; Medical research; Metastases; Molecular modelling; Non-small cell lung carcinoma; nonsmall‐cell lung cancer; Tumor microenvironment; Tumorigenesis
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.34127

Lung cancer is the common and leading cause of cancer death worldwide. The tumor microenvironment has been recognized to be instrumental in tumorigenesis. To have a deep understanding of the molecular mechanism of nonsmall cell lung carcinoma (NSCLC), cancer‐associated fibroblasts (CAFs) have gained increasing research interests. CAFs belong to the crucial and dominant cell population in the tumor microenvironment to support the cancer cells. The interplay and partnership between cancer cells and CAFs contribute to each stage of tumorigenesis. CAFs exhibit prominent heterogeneity and secrete different kinds of cytokines and chemokines, growth factors and extracellular matrix proteins involved in cancer cell proliferation, invasion, metastasis and chemoresistance. Many studies focused on the protumorigenic functions of CAFs, yet many challenges about the heterogeneity of CAFS remain unresolved. This review comprehensively summarized the tumor‐promoting role and molecular mechanisms of CAFs in NSCLC, including their origin, phenotypic changes and heterogeneity and their functional roles in carcinogenesis. Meanwhile, we also highlighted the updated molecular classifications based on the molecular features and functional roles of CAFs. With the development of cutting‐edge platforms and further investigations of CAFs, novel therapeutic strategies for accurately targeting CAFs in NSCLC may be developed based on the increased understanding of the relevant molecular mechanisms.